From

The Director General Health Services, Haryana, Swasthya Bhawan, Sector 6, Panchkula, E-mail: dhs.idspdatam@hry.nic.in

To

All Civil Surgeons, Haryana.

No. 32/3-IDSP/2020- 1917 - 38

Dated: 03/04/2.2.

#### Subject: Regarding guidelines of surveillance of COVID 19 in Haryana.

In Continuation of Letter No. 32/3-IDSP/2020-137-59 dated 24/01/2020 vide which it was conveyed that IDSP has to put travelers coming from affected areas of COVID-19 are to be put under surveillance as per GOI protocol and reporting format were also shared with the letter. Now as you know that positive cases are reported from our State so we need to emphasize more on contact tracing activity under Surveillance. In this context, we are sending you detailed instructions that how to carry out surveillance in present situation.

### **Updated Case Definitions**

1. Suspect Case: A patient with acute respiratory illness {fever and at least one sign/symptom of respiratory disease (e.g., cough, shortness of breath)}, AND A history of travel to or residence in a country/area or territory reporting local transmission of COVID-19 disease during the 14 days prior to symptom onset; OR

A patient/Health care worker with any acute respiratory illness AND having been in contact with a confirmed COVID-19 case in the last 14 days prior to onset of symptoms; OR

A patient with severe acute respiratory infection {fever and at least one sign/symptom of respiratory disease (e.g., cough, shortness breath)} AND requiring hospitalization AND with no other etiology that fully explains the clinical presentation; OR

A case for which testing for COVID-19 is inconclusive.

#### Action to be taken at District level

- Put suspect case into isolation ward designated exclusively for suspect cases of COVID19 and take sample according to the lab protocols already shared, observing proper personal protection protocol and send sample for testing at approved Lab.
- Patient will remain in isolation ward till result of report declared, if result comes negative assess clinical condition of the patient and put under Institutional quarantine (High Risk) /home quarantine (Low Risk).
- 2. Laboratory Confirmed case: A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms. Action to be taken:
- Shift person into isolation ward designated exclusively for Confirmed COVID19 cases.
- Manage case according to Clinical Management Protocols.
- When recovered then discharge according to discharge policy and put patient under 14 days home quarantine.

Contact Tracing On getting information about positive case IDSP team has to trace contacts of positive case according to the definition of contacts provided below. Then categorize them into High Risk and Low Risk. High Risk Contacts are to be kept in quarantine facility and low risk contacts are needed to put under home quarantine.

**Definition of Contact**: A contact is a person that is involved in any of the following:

• Providing direct care without proper personal protective equipment (PPE) for COVID-19 patients

· Staying in the same close environment of a COVID-19 patient (including workplace, classroom, household, gatherings).

• Traveling together in close proximity (1 m) with a symptomatic person who later tested positive for COVID-19.

### High Risk Contact:

• Touched body fluids of the patient (Respiratory tract secretions, blood, vomit, saliva, urine, faeces)

• Had direct physical contact with the body of the patient including physical examination without PPE.

- Touched or cleaned the linens, clothes, or dishes of the patient.
- Lives in the same household as the patient.
- Anyone in close proximity (within 3 ft) of the confirmed case without precautions.

• Passenger in close proximity (within 3 ft) of a conveyance with a symptomatic person who later tested positive for COVID-19 for more than 6 hours.

#### And/ or

- Elderly (Age more than 60 years)
- Hypertensive
- Diabetic
- Asthmatic
- And any other condition leading to potential immunodeficiency.

#### Action to be taken

- Put contact into quarantine facility designated for high risk contacts and take sample of high risk contact on 14<sup>th</sup> day of quarantine by observing proper personal protection protocol and send sample for testing.
- Contact will remain in quarantine facility till result of report declared, if result comes negative, discharge person and keep them under **home quarantine**.

#### Low Risk Contact:

- Shared the same space (Same class for school/worked in same room/similar and not having a high risk exposure to confirmed or suspect case of COVID-19).
- Travelled in same environment (bus/train/flight/any mode of transit) but not having a high-risk exposure

#### Action to be taken

• Put contact into home quarantine.

#### Surveillance Protocol

The various persons shall be put on surveillance in the following facilities as per the following matrix :

	Home Quarantine	Institutional Quarantine	Isolation for Suspected cases	Isolation for confirmed cases
Category (Confirmed Case)				Cubes
Category (Suspect Case)				
Category (High Risk Traveller or Contact)				
Category (Low Risk Traveller or Contact)				

#### **Important Directions**

- Designate one officer for filling Case Investigation form (enclosed at Annexure A along with SOP and Letter from GOI) of the positive confirmed COVID19 case. This form filling will be based on interview of clinician and telephonic interview with patient. Officers can be District Immunization Officer or Urban Nodal Officer along with one nodal person of isolation facility where patient is admitted as they are already familiar with case investigation form. WHO will provide technical support for the same.
- Model Micro Plan received from GOI is enclosed at Annexure B. In it there at Annexure II and III at Page 15 and 16 along with appendix V and IX i.e page no. 19 and 24 respectively for the data collection and reporting of Surveillance during Containment and Local Active Surveillance. It will be filled by DSO in coordination with DIO.

- In case of referral of positive case to higher medical institute / tertiary health facility then • Annexure VI(of attachment Annexure B) on page 20 has to filled by the clinician.
- If person under home quarantine remains asymptomatic after 14 days of observation, he/she should be advised/ requested to self-monitor for development of symptoms like fever, cough and/or breathing difficulty for next 14 days.
- Surveillance reporting period is 28 days. If a person remains asymptomatic after 28 days of observation no further action is required.
- If person becomes symptomatic any time during Home Quarantine and Institutional Quarantine or in self monitoring time, then he/she shall be categorized as suspect case and shifted to isolation facility for suspect cases for further investigation and management.
- All low risk contacts to be tracked, home quarantined and lab-tested only when symptoms appear.
- All high risk contacts to be tracked, quarantined in quarantine facility and lab-tested.
- Kindly mention the information of completion of 28 days (for travelers/contacts) in the remark column mentioned in the line listing (Format B).
- Information regarding any change in the status of the positive patient like getting critical or discharged from the facility should be shared with State Surveillance Unit immediately.

All reports related to surveillance activities need to be sent at <u>dhs.idspdatam@hry.nic.in</u> along with consultantidsphry@gmail.com upto 11:00 AM daily.

All reports related to lab and samples need to be shared at <u>dhs.idspdatam@hry.nic.in</u> along with covidlabhry@gmail.com upto 11:00 AM daily.

Hence, you are requested to ensure all above mentioned directions are to be followed strictly in your district so that Health Department can contain spread of COVID-19 infection efficiently.

O Director Health Services (IDSP), C O/o Director General Health Services, Haryana, Panchkula.

#### Endst. No. 32/3-IDSP/2020- 1939-40

Dated: 03/04/2.20

## A copy is forwarded to the following for information, please:

- 1. PA to Mission Director, National Health Mission, Haryana
- 2. PA to Director General Health Services, Haryana.

Director Health Services (IDSP), O/o Director General Health Services,

Haryana, Panchkula.



भारत सरकार **राष्ट्रीय रोग नियंत्रण केन्द्र** (स्वास्थ्य सेवा महानिदेशालय) स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार 22, शाम नाथ मार्ग, दिल्ली - 110054



23922132 Fax: 23922677

**Government of India** 

IFormally Known as National Institute of Communicable Disease (NICD) Directorate General of Health Services

Ministry of Health & Family Welfare, Government of India 22, Sham Nath Marg, Delhi-110054 E-mail: dirnicd@nic.in, sujeet647@gmail.com Website: www.ncdc.gov.in D)] www.idsp.nic.in

Direct: 00-91

File No: T- 18015 / 307/2020 - TDSP Dated the: 31<sup>st</sup> March 2020

Sir/Madam,

Dr. Sujeet K Singh

MD, DCH

Director

First of all, I would like to congratulate you for putting up an tremendous work in containment of COVID-19 in your States. In view of the upsurge in number of COVID-19 cases in India with rise in involvement of multiple States and Union Territories, there is huge requirement of Human Resources for management of correct data for analysis and decision making at the competent authority level.

It becomes difficult to get clarity on picture for the country when the data is either incomplete or not clear. In this regard, an expert committee has decided to revise the case investigation form (CIF) which is enclosed with this letter and you can take support of WHO-NPSP to get the CIF filled for all the confirmed and suspected cases in your State. Standard Operating Procedure (SOP) for filling up of the CIF has been attached for your reference.

The filled CIFs need to be shared with the Central Surveillance Unit (CSU), IDSP NCDC for better utilization of data for further policy decisions.

With regards,

Enclosures:

- 1. Case Investigation Form for COVID-19 (CIF)
- 2. SOP for filling the Case Investigation Form

Yours sincerely,

(Sujeet Kumar Singh)

Τо,

#### Mission Director of all States/UTs

Copy for information to:

- 1. Principal Secretary Health and Family Welfare of all States/UTs
- 2. State Surveillance Officers of all States/UTs
- 3. WHO Representative to India, India Country Office
- 4. Team Leaders WHO-NPSP of all States/UTs





#### Form A NATIONAL CENTRE FOR DISEASE CONTROL (To be filled COVID-19 Acute Respiratory Disease)

To be filled at NCDC

A	PATIENT INFORMA	HON								
1.	Name of patient:		Age: Gende	yrmo (/ r: M/F	/)		Date of interview:			
2.	Name of Health Fac isolated:	e of Health Facility where District (Is ted:					solation facility):			
3.	Name of interviewe	er	Designa	tion of interviewer:		Contact I	Number of interviewer			
4.	Case Classification:	Confirmed		Suspect						
5.		Current status of case: Stable 🗆 Admitted in ICU 🗆 Deceased 🗆								
	SOCIODEMOGRAPI	and the second				- Iliniano				
	Nationality: India	n			-Indian (Name	Contraction of the second	y)			
	Father's name:			House No.		the local division of the second division of	Setting: Rural / Urban			
	Village/Mohalla: Block:		Distric State:	:t:	Phone r email ic	number: l:				
2	CLINICAL INFORMA	TION								
L	Patient clinical cou	rse								
1.1	Date of Onset of sy	mptoms:	/	/; Initial Syr	nptoms:					
1.2	Details of contact v	vith heath fac	cility after	the date of onset						
	Details of contact with nearn fact       Name of facility:       Address:       Phone number:			2	3		4			
	Dates case visited:			Vee (Ne	Vac/No		Yes/No			
	Did health facility report the case	Yes/No		Yes/No	Yes/No		Yes/No			
1.3	Date of admission									
1.4				ischarged/ LAMA/ Diec	1.5Date	e of outco	me (if applicable)			
1.6	Cause of death (As	and the second s	and a second of the second sec	And the second						
2	Patient Symptoms	at admissio		Construction of the second s			N			
a)	Fever/chills		b)	Sore throat		<u>c)</u>	Nausea/Vomiting			
d)	General weakness		<u>e)</u>	Breathlessness		f) i)	Headache			
g) i)	Cough Runny nose		h) k)		A REAL PROPERTY OF A REAP		Irritability/confusion Any other(specify)			
3	Patient signs at ad	mission: Dot	i ails of fol		on from the cas	e sheet if	the patient is admittee	4		
a)	Temperature (in Fa		b)	Abnormal Lung X-Ra findings: Yes / No		c)	Coma: Yes / No			
d)	Stridor: Yes / No		e)	Tachypnoea: Yes / N	0	f)	Seizure: Yes / No			
g)	Redness of eyes: Y	es / No	h)	Abnormal lung auscu		lo i)	Any other(specify):			
4	Underlying medica	al conditions	(encircle	all that apply)				1		
a)	COPD		b)	Hypertension		c)	Chronic neurological on neuromuscular diseas			
d)	Chronic Renal Dise	ease	e)	Asthma		f)	Heart disease			
g)	Bronchitis		h) (t)	Pregnancy rimester)		i)	Immunocompromised including HIV, TB	d conditio		
j)	Malignancy		k)	Post-partum (< 6 we	eks)	1)	Any other (mention)			
m)	Diabetes		n)	Liver Disease		o)	None			
D	EXPOSURE HISTO					1122	202 Ba			
5	Occupation (circle (specify)		Businessm	an/ Health care worke	r/Health care l	ab worker	/ animal handler/ any	other		
		00100 10	so lonciro	le): Lab confirmed case	of COVID-19	Suspect of	case under investigatio	n / No		
6						umber: CC	DV-IND-			
	contact / Not know	wn; (If conta	ct with La	b confirmed case, men	tion its EPID n	and the same and the same state of the same stat				
5 6.1 a)	contact / Not know	wn; (If conta ab confirmec	ct with La d COVID-1		tion its EPID no contact setting	and the same and the same state of the same stat				

c)	Clinical care of o HCW)	case (among	d)	Immigration Staff at (details of place)	Point of Entry	e) Housekeeping (H			
f)	Caregiver of the details of case)	e case (specify	g) Living in the same household			h) Providing service:	s to the household		
i)	Living in the nei	ghborhood	j)	Others, Specify					
7	and the second sec	mber of a cluster or COVID 19? Y		ts with severe acute r	espiratory illness (	e.g., fever and pneumo	nia requiring		
8				g in last 1 month? (Ye	es/No/Unknown) i	f yes, specify:			
			0	0			Sector Sector		
E	TRAVEL HISTOP								
9	Have you trave	lled outside India	a in the pa	st one month? Yes/ N	No. If yes, then fill c	letails in Q. 9.1 onward	s else skip to Q.10		
9.1	Name of the co	untry (City)		Date of arrival		Date of departure			
9.2	Did you visit W	uhan (yes/no)	During	your stay, did you vi	sit any animal marl	ket? Yes/No			
9.3	Date of arrival i	n India (Includin	g transit fl	lights in India):/	/Flight	t No: Se	eat No:		
10	Have you trave	lled within India	in the pas	t one month? Yes/ No	o. If no, skip to Sec	tion F			
	If yes, details of	f places visited in	chronolo	gical order: flight / tr	ain / vehicle numb	er; seat/berth, coach n	umber etc		
a)	Place & Duratic	- International second of the second s		f arrival:		Mode of travel:			
1									
			Date o	f departure:		Details:			
b)	Place & Duratio	on of stay:	Date o	f arrival:		Mode of travel:			
							a ter Malas		
			Date o	of departure:	1. 1. A. 1. 2. A. 1.	Details:			
		<i>c</i> .	-	· · ·					
c)	Place & Duratio	on of stay:	Date o	of arrival:		Mode of travel: Details:			
			Date c	of departure:					
F		INFORMATION (	to he obta	ained from treating p	hysician (DSO)				
11	Construction of the second second second second second by the second	Construction of the second s	Contraction in the second second large a real	the restriction of the second	a construction and the second second second second and the	s and update the result	c		
a)	Type of	Name of sam		Date of sample	Sent to which	Result	Date of		
	sample collected	collection ce		collection	Lab	(Positive/Negative)	lab result		
		-							
	Reason if sample	a not collected:				1	I		
b)	· · · · · · · · · · · · · · · · · · ·	at confirmed res	ult:						
G				e where applicable					
12a)	Hospitalization		ing Erren en	Date of hospitalizat	ion:				
b)	ICU Admission:			Date of ICU admiss		Date of discharge from	ICUI		
~)	the second s	ntilation: Yes / N	0	Date of mechanical		bate of discharge from	100.		
	incentanical vel	nanaciona res / N	0	Date of mechanical					
	ARDS: Yes / No				ilure: Yes / No				
		bost V rous Vor /	No						
	the second s	hest X ray: Yes /		and the second provide the second s	al Failure: Yes / No				
	control and the second	agulopathy: Yes	/ 100	Other com	plication: Yes / No,	if yes please specify:			
H	PUBLIC HEALTH	and the second s			N. 51.1.1.1				
a)		h risk contacts: _			No. of high risk cor				
		collected in high		icts:;	No. of high risk cor	ntacts developed sympt	oms;		
	state and and the second s	contacts tested p	ositive:						
b)	Total no. of low				risk contacts becom				
	No. of low risk contacts tested: No. of low risk contacts tested positive:								

# SOP (Standard Operating Procedures) for investigation of a suspected COVID- 19 case using Case Investigation Form (CIF)

Case investigation is crucial for the disease confirmation and to identify the magnitude of public health response. All suspected COVID-19 cases notified as per the case definition should be investigated by a clinician/medical officer within 24 hours of case-notification using the standardized Case Investigation Form, if it comes under the following case definitions.

#### **COVID-19 Case Definitions**

#### Suspect Case:

A patient with acute respiratory illness (fever and at least one sign/ symptom of respiratory disease (e.g., cough, shortness of breath) AND a history of travel to or residence in a country/area or territory reporting local transmission (See NCDC website for updated list) of COVID-19 disease during the 14 days prior to symptom onset;

OR A patient / health care worker with any acute respiratory illness AND having been in contact with a confirmed COVID-19 case in the last 14 days prior to onset of symptoms;

OR A patient with severe acute respiratory infection (fever and at least one sign/symptom of respiratory disease (e.g., cough, shortness of breath) AND requiring hospitalization AND with no other aetiology that fully explains the clinical presentation;

OR A case for whom testing for COVID-19 is inconclusive

Laboratory Confirmed case: A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

The detailed information of the suspected case along with core variables should be captured in both pages of the CIF by the investigating officer.

#### Key components for filling up the Case Investigation Form:

- Fill-up the "Case Investigation Form" (CIF) on both pages during examination
- Allot EPID no, a unique identifier for every suspected case that is investigated
  - Eg. COV-IND-ST-DIS-YR-Case number
  - First 3 character signifies disease, next 3 characters for country code, next 2 for state code, next 3 for district code, next 2 for year of disease onset and next 4 is the serial no. of the case in that year in the same district
  - Ex: First case of Patna Bihar: COV-IND-BI-PAT-20-0001
  - DSO should assign this EPID no for every investigated case on CIF.

COVID-19 CIF SOP

Page 1 of 3

Any error in the Epid No. may misclassify the cases

- A. Complete case identification details including name, age, sex, details of isolation facility, case classification and status
- B. Collect socio demographic details of case like father's name, address and contact details
- C. Take clinical history and examine the suspected COVID-19 case for signs and symptoms
  - Date of onset of symptom is the most important date which should be strictly assessed along with nature of initial symptom (for eg. bodyache/fever/cough /breathlessness/sore throat etc.)
  - Fill-up the health facility contacts after date of onset of symptom. These are the hospitals/ clinic, case has taken consultation/treatment before getting reported, which will further help to identify the need to build the capacity
  - Capture the signs, symptoms at time of admission
  - Capture the underlying medical conditions
- D. Exposure history:
  - Take significant exposure history of suspected case, to identify the person/area/country from where case picked up infection
  - Explore further contact setting if there is exposure to lab confirmed COVID-19 case including exposure while taking samples, during travel/clinical care of case/living in same household/providing services to the same household
  - Seek history about occurrence of cluster of patients with severe acute respiratory illness or COVID-19 at his place of residence/work/neighbourhood
  - Explore exposure to mass gathering in past one month before the onset of symptom
- E. Travel history:
  - Take epidemiologically significant travel history of suspected case for travel outside and within India for past one month before the onset of symptom
  - Patient travel history can be taken in chronologic order starting from one month back from onset of symptoms
- F. Laboratory Information:
  - The clinician should decide necessity for collection of clinical specimens for laboratory testing of cases only after following the case definition as given by the health authorities, Government of India.
  - Appropriate clinical sample need to be collected by laboratory personnel/ health care
  - worker trained in specimen collection by following all biosafety precautions and using personal protective equipment (PPEs)
  - Clinical samples need to be sent to the designated laboratory by following standard triple packaging

COVID-19 CIF SOP

Page 2 of 3

- Collect the information on the sample collected including type of sample, name of sample collection centre, date of sample collection, sample shipment to laboratory and results
- Identify and mention the reason for not collecting samples
- G. Patients Symptoms:
  - Collect hospitalisation history including onset of any complications
- H. Public Health Response:
  - Identify high and low risk contacts
  - High-risk contact includes:
    - Lives in the same household as the confirmed case.
    - Touched body fluids of the confirmed case (respiratory tract secretions, blood, vomit, saliva, urine, faeces)
    - Had direct physical contact with the body of the confirmed case including physical examination without PPE.
    - Touched or cleaned the linens, clothes, or dishes of the confirmed case.
    - Anyone in close proximity (within 1 m) of the confirmed case without precautions.
    - Passenger in close proximity (within 1 m) of a conveyance with a symptomatic person who later tested positive for COVID-19 for more than 6 hours.
  - Low-risk contact include:
    - Shared the same space (same class for school/worked in same room/similar) and not having a high-risk exposure to confirmed case of COVID-19.
    - Travelled in same environment (bus/train/flight/any mode of transit) but not having a high-risk exposure.
  - Collect the information on number of high risk contacts traced, numbers quarantined, numbers of these high-risk contacts tested and subsequently turning out positive for COVID-19
  - Collect the information on low risk contacts traced and number of such contacts turning symptomatic and tested for COVID-19.

Important: Keep the CIF updated with all information including health facilities visited, laboratory results and public health response

**Model Micro-Plan** 

# Micro Plan for Containing Local Transmission of Coronavirus Disease (COVID-19)

Epicentre ---------- Block, ----- District, ----- State

## Micro-plan for Containing Local Outbreak of COVID-19

Geographic Location: ------Municipality, ------ Block, ------ District, ------ State

1. Objective of the micro-plan

To contain the outbreak of COVID-19 in defined geographic area

# 2. Demographic details (for each district coming under containment and buffer zones separately, as defined in Section 3)

District details

District area: District Population: No of Blocks: No of Municipalities:

**Block Details** 

Name of Block: Population: Number of Villages:

#### **3.** Mapping the affected area

The containment zone will be decided by the RRT based on the extent of cases/contacts listed and mapped by them. However if contact listing/ mapping is taking time (>12-24 hours), then on arbitrary basis demarcate an area of 3 Kms radius around the epicenter (the residence of the positive case). This area of 3 km radius will be the containment zone. If required, based on the mapping of contacts and cases, the containment zone will be refined.

A buffer zone of an additional 5 Kms radius (7 Kms in rural areas)/administrative boundary of including neighboring districts/per-urban zone shall also be identified, as detailed in the cluster containment plan.

3.1 Affected area (Containment Zone – As per Cluster Containment Plan)

Name of the epicentre: Municipality ward/ village: Number of affected Municipalities /villages: Number of Villages/ Wards in Containment Zone: Number of houses in containment zone: Population in Containment Zone: 3.2 Buffer Zone – As per Cluster Containment Plan

Number of Municipalities /villages: Number of Villages/ Wards in Buffer Zone: Number of houses in Buffer zone Population in Buffer Zone:

3.3 The containment zone will be divided into sectors with 50 houses each (30 houses in difficult areas). The sectors will facilitate all activities for containment as described in the ensuing sections/ paragraphs.

# Every confirmed case has to be considered as an epicenter and micro-plan activities will be done as described above.

Divide the area into sectors. List them with name (of village) and identified nodal officer.

Listing of Sectors

Sector	Name of Sector	Nodal Officer	Contact number
А			
В			
С			
D			

#### 4. Human Resource

#### 4.1. Administrative and Technical Personnel

The District Collector/District Magistrate will be Nodal person for cluster containment in their respective districts.

S. No	Name	Designation	Contact Number (O)	Mobile
1		DM/District Collector		
2		ADM		
3		CDMO		
4		BDO		
5		Block MO		
6		Block AHO		
7		BEE		
8		NHM Block Manager		

#### State RRT

S. No.	Name	Designation	Contact Number (O)	Mobile
1				
2				
3				

#### **District RRT**

S. No.	Name	Designation	Contact	Mobile
			Number (O)	
1				
2				
3				

#### 4.2. Human Resource for operations / field activities

#### 4.2.1 Responsibilities assigned to various functionaries

#### 4.2.1.1 ASHA/ ANM/ Anganwadi worker\*:

- 4.2.1.1.1. Daily house to house visit to:
- (i) Search clinically suspect cases.
- (ii) Identify contacts of confirmed and suspect cases
- (iii) Maintain line list of suspect/ confirmed cases and contacts
- (iv) Monitor contacts daily
- (v) Inform Supervisory Medical Officer about suspect cases and their contacts
- (vi) Create awareness among community about disease prevention, home quarantine, common signs and symptoms and need for reporting suspect cases by distributing fliers, pamphlets and also by inter-personal communication.

4.2.1.1.2. Counsel individuals to take precautions to avoid contact with those with symptoms suggestive of COVID-19.

4.2.1.1.3. Ensure that contacts are on home quarantine use 3 layered surgical masks at all times. Educate them on proper use and disposal of masks. The team will also educate the family members about precautions to be taken while taking care of persons under home quarantine.

\* If there is human resource constraint to engage as many ASHA/AWW/ANMs, then Indian Red Cross society/NDRF/Civil Defence/NSS/NCC volunteers available in the district shall be engaged after proper briefing on roles and responsibilities and infection, prevention and control practices.

#### 4.2.1.2. LHV/ MPWMW

- Supervisory duty at the village/ block covering the epicenter.
- Daily visit to allocated sectors to oversee and cross-check the activities of ASHA/Anganwadi workers/ ANM.

Report on real time basis, any person reporting of symptoms of COVID-19.

#### 4.2.1.3. Block Extension Educator and other communication staff

- Public information education and communication campaign targeting schools, colleges, work place, self-help groups, religious leaders, teachers, postman etc.
- Arrangement of miking.

#### 4.2.1.4. Municipal/ village Panchayat staff / Civil society volunteers

- Create awareness in the community
- Encouraging community to follow frequent hand wash, respiratory etiquettes, selfmonitoring of health and reporting to the health workers about persons in their vicinity having cough, fever, breathing difficulty.

#### 4.2.1.5. Supervisory Officer

- Supervises the field work
- > Verifies suspect case as per case definition.
- > Arranging shifting of suspect case to health facility.
- > Random Check of persons under home quarantine.
- Submit daily report to control room

#### 4.2.1.6 Block NHM Manager/ any other designate of DM

- > Information management with in the containment zone
- > Contingency funding of the containment operations
- Managing finances.

#### 4.2.2. Norms for deployment of human resource:

A health care worker (ANM/ ASHA/Anganwadi Worker) will be able to visit 50 houses in a day (30 in difficult areas).

A supervisory Medical Officer shall be deployed to cover 1000 population.

S. No.	Designation of staff	Nature of work assigned	No. of personnel deployed for containment operation	Mobilized from within the District	Mobilized from adjoining District
1.	District Collector or his assignee	Incident Command			
2	Central/ State RRT	Planning and operations			
3	Sector Medical Officers	Supervisory			
4	LHV	Intermediate Supervisory			
5	ANM/ ASHA/ Anganwadi Worker	Field work			
6	Block Extension Educator and other communication staff	IEC			
7	Municipal/ village Panchayat staff Civil society volunteers	Community mobilization			
8	NHM -District/ Block Manager	Logistics Information Management Financial management			

#### 4.2.2 Human Resource requirement for field operations

#### **5.** Components of Micro-plan

#### 5.1 Surveillance

#### 5.1.1. Active Surveillance

5.1.1.1. Constituting Teams for Human Health Surveillance:

Each health worker would cover 50 houses in the sector assigned to them. The listing of municipality wards/ villages allocated to surveillance teams, their names, name of supervisors for each team and their contact number is at **Annexure-I** 

#### 5.1.1.2. Assigning Tasks to the Teams

The Medical Officer in-charge will assign tasks as listed in para 4.2.1 to the Supervisory Officer/ANM/ASHA/Anganwadi Worker.

During the course of their house to house visit, the ANM/ASHA/Anganwadi Worker will identify suspect case, if any, as per case definition. The name, age, sex, and the address of such persons to be recorded on proforma at **Annexure-II.** The Health worker will counsel household members to take basic precautions to avoid direct contact with a suspect case. He / she will provide a mask to the (i) suspect case (till such time he/she is examined by the supervisory officer).

The concerned ANM/ASHA/Anganwadi Worker will immediately inform his/her supervisory officer about the suspect case.

## **5.1.1.3.** Role of Supervisory Medical Officer/ LHV

The door to door surveillance will be supervised by Medical Officers/ LHV assigned sectors within the defined surveillance zone. He/she will also collect data from the health workers under him/ her, collate and provide the cumulative data to the control room by 4.00 P.M.

He / she will visit any suspect case brought to his/ her notice by the ANM/ASHA/Anganwadi Worker during their daily house to house visit. He/ she will immediately call for the ambulance and ensure transfer of the patient to identified hospital after ensuring on the basic precautions. Details of the registration number of the ambulance, shifting time to the hospital and contact number will be kept and conveyed to the Control Room.

Name of the patient being shifted	Age	Sex	Ambulance No.	Name of the driver/ Paramedic	Contact number	Time Shifting	of

#### 5.1.2. Passive Surveillance

All health facilities in the containment and buffer zones will be listed. All such facilities both in Government and Private sector (including clinic) shall report clinically suspect cases of COVID-19 to the identified supervisory officer for that sector. Proforma for reporting suspect COVID-19 cases by health facilities is at **Annexure-III.** 

#### 6 Contact Tracing

The contacts of the laboratory confirmed cases/ suspect cases of COVID-19 will be linelisted. The Supervisory officer in whose jurisdiction, the laboratory confirmed case/ suspect case falls shall inform the Control Room about all the contacts and their residential addresses. The control room will in turn inform the supervisory officers of concerned sectors for surveillance of the contacts. These contacts will be tracked by assigned ANM/ASHA/Anganwadi Worker of that sector and kept under home quarantine for 14 days. They will be monitored for clinically compatible signs and symptoms of COVID-19 for 28 days in total. If the residential address of the contact is beyond the containment zone or in adjoining district / State, the district IDSP will inform the concerned District IDSP.

Detail guidance for contact tracing, quarantine and isolation is given at **Annexure –IV**. Proforma for line listing of contacts is at **Annexure-V**.

#### 7. Laboratory Support

The microbiologist in the Central/State RRT will be responsible for managing laboratory Support. He/ She will identify nearest VRDL network laboratory for logistic support for sample collection, packaging and transportation. The doctors manning the isolation facility will be trained by the RRT and they shall be responsible for sample collection, packaging and transportation. The sample collection proforma to be attached with the samples is at **Annexure-VI**.

Name of the VRDL Laboratory	Name of Nodal person	Contact number

#### 8. Identified Health Facility

8.1. The Physician in the RRT will visit the nearby hospitals and identify the nearest hospital best suited for isolation and tertiary care/ medical college best suited for Ventilator management/ critical care management/ Salvage therapy (ECMO).

Name of the identified	Name and Contact	Name and	Contact details
health facility	details of MS	contact details of	of Emergency
		Nodal officer	

The details of the identified facilities will be informed to all the Supervisory Officers by the NHM District/ Block manager.

All suspect cases of COVID-19 will be admitted to the above identified health facility. The Supervisory Medical Officer, in whose Jurisdiction the case is reported,

shall ensure his/ her hospitalization. The hospital will be informed in advance about the referral case.

Reporting format for health facilities identified for isolation/critical care management of COVID-19 cases is at **Annexure III.** 

#### 8.2. Ambulance facility

There will be earmarked ambulance for the transfer of patients. The drivers will be trained in infection prevention and control practices and also in disinfection of ambulance after transporting suspect cases. Drivers of these ambulances will be provided with appropriate PPE depending on the risk assessment conducted by district/RRT epidemiologist.

Date	Shift	Name	of	the	Name	of	the	Contact	numbers
		driver			Paramedic			(Driver	and
								Paramedi	c)
	8:00 AM -								
	2:00 PM							-	
	2:00 PM -								
	8:00 PM								
	8:00 PM -								
	8:00 AM								

## 8.3 Hospital infection prevention and Control

The Microbiologist in the RRT will train the health workers on infection prevention control practices prior to their field assignment. They will also train the identified field functionaries on donning and doffing of PPE. The PPEs are to worn as per the risk assessment for various categories of personnel.

S. No	Name of the item	Remarks
1	Full complement of PPE (N 95 Mask, Gloves, Goggles, coveralls, headgear, foot wear)	<ul> <li>To be used by:</li> <li>Doctors attending to patients in health facilities in the containment zone and referral hospital for isolation/ critical care, where aerosolization can occur (like intubation, non-invasive ventilation, tracheostomy, and manual ventilation before intubation, suction etc.)</li> <li>Doctors collecting samples.</li> <li>EMTs attending patient in ambulances</li> <li>Staff in the laboratories</li> </ul>
2	N-95 Mask and gloves	• To be used by supervisory doctors verifying a suspect case

		• Doctors/nurses attending patients in screening clinics/OPD
3	N-95 mask, gloves	• Sanitary workers involved in sanitation and disinfection activities for COVID-19 cases
4	Triple Layer medical mask/ examination gloves	<ul> <li>To be used by:</li> <li>field workers,</li> <li>suspect cases and</li> <li>care giver / by stander of the suspect case</li> <li>Ambulance drivers.</li> <li>All functionaries at the perimeter control.</li> </ul>

#### 10. Logistics

#### 10.1. PPE

All PPE will be used rationally. RRT members will train the identified field functionaries on donning and doffing of PPE. The PPEs are to worn as per the risk assessment for various category of personnel.

The following daily log on PPE will be maintained:

S. No.	Name of the item	Opening	Nos. used	Closing	Remarks
		balance for	with in the	balance	
		the day	day		
1	PPE Kits				
2	N-95 Mask				
3	Triple Layer				
	Surgical mask				
4	Gloves				
5	Biohazard bags				

All PPEs to be disposed of in a Biohazard Bag (yellow). The outer surface will be disinfected using 1% Sodium Hypochlorite spray.

#### 11. Communication

Block Extension Educator / or any other designated communication staff will be allocated the work of public education outreach on COVID-19. Public information education and communication campaign shall target schools, colleges and work place within the

containment zone. The key messages (including that used for Inter-personal Communication) have already been conveyed to the States.

The sector wise allocation of BEE their name and contact no. will be listed. Municipal/ Village Panchayat Officers will be allocated sectors with in the surveillance zone for encouraging and participating in public awareness campaigns and participation. The rostering of staff for public education outreach is at **Annexure-VIII**.

#### 12. Data Management

The Control Room will have data managers (deployed from IDSP/ NHM) responsible for collecting, collating and analyzing data from field and health facilities. They will work in 3 shifts. Data Collection tools will form **Annexure-IX** of this document. Output variables to be generated at micro level on daily basis;

No. of Suspect case of COVID-19
No. of laboratory confirmed case
No. of deaths
No. of contacts line listed:
No. of contacts tracked:
No. of contacts currently under surveillance:
No. of contacts which have exited the follow up period of 28 days:

#### 13. Control Room

The following details will be provided under this head: Nodal Officer with contact number: Control Room Number:

#### 14. **Office orders (indicative)**

Orders on notification. Order for taking services of personnel

#### **15.** Budgeting (indicative)

S.no	Item	Unit cost	Total cost	
1.	Transportation			
	No. of vehicles hired			
	POL expenditure for Office vehicles/ ambulances			
2.	Communication			
	Cost of printing posters			
	Hiring personnel for display			
	of posters			

	Cost of hiring vehicles for miking		
	Advertisement cost : local dailies cable network local TV channels		
	SMS		
3	Logistics		
	Three layered surgical mask		
	N 95 mask		
	PPE		
4	Contingency Expenditure		

#### Annexures

Annexure No.	Subject
Ι	Containment zone: Identified Sectors for surveillance
II	Data collection tool at field level
	Data collection tool at field level (Field Level Data
	Compilation Sheet)
III	Daily Line listing of Patients detected at health facilities
IV	Recommended guidance for contact tracing, quarantine and
	isolation for Coronavirus Disease (COVID-19)
V	Line listing of Contacts
VI	Sample collection proforma to be attached with the samples
VII	Transportation arrangement for containment Operation
VIII	Identified Sectors for Public Education Outreach and rostering
	of identified communication staff
IX	Daily report of COVID-19 Outbreak

### Annexure-I

Containment zone: Identified Sectors for surveillance

Sector	Name of	Name of ANM/	Contact	Name of	Contact
	Municipal	ASHA/Anganwadi	Number	Supervisory	Number
	ward/ village	Worker		Officer	

### Annexure-II

#### Data collection tool at field level (Line listing of suspect cases)

:	
:	
:	
:	Phone:
:	Phone:
:	Phone:
	: : : : : : : : : : : : : : : : : : : :

S.No	Name of patient	Age	Sex	Address	c/o Fever, Cough, Difficulty in breathing	Remarks

### Data collection tool at field level (Field Level Data Compilation Sheet)

S. No.	Name of village	Total population surveyed	Μ	F	No. of Suspect cases identified	Total number of contacts put under home quarantine	Remarks
Total							

## Annexure-III

## Daily Line listing of Patients detected at health facilities

S. No	Name	Age	Sex	Address	Symptoms or contact with COVID-19 suspect case	Sample taken (Y/N)	Remarks

**Recommended guidance** for contact tracing, quarantine and isolation for Coronavirus Disease (COVID-19):

#### I. Contact Tracing:

- **a.** Contact means a person:
  - Providing direct care without proper personal protective equipment (PPE) for COVID-19 patients
  - Staying in the same close environment of a COVID-19 patient (including workplace, classroom, household, gatherings).
  - Traveling together in close proximity (1 m) with a COVID-19 patient in any kind of conveyance within a 14-day period after the onset of symptoms in the case under consideration.

#### b. Each worker or person responsible for contact tracing should:

- Enlist all the contacts for tracing along with their names, address and contact details and submit to the supervisor daily
- Daily visit the contact and ask him/her if had developed any fever, cough, shortness of breath, difficulty in breathing etc.)
- Educate contacts and their family members on importance of contact tracing and home quarantine
- Distribute Triple layer surgical masks to the contact and keep sufficient stock.
- Create awareness on symptoms and provide information on self-health monitoring
- Contacts should be informed that if they develop symptoms:
  - Immediately wear a triple layer mask and avoid close contact with any other person.
  - Inform concerned health worker who will arrange for medical examination by supervisory medical officer and transportation to hospital, if required.
  - Provide details on all possible contacts since the time he/she has developed symptoms and inform health worker
- Duration of follow up of contacts would be 28 days from the time of last contact with a case

#### II. Active surveillance:

Active surveillance shall be done within containment zone (or 3 Km radius from the periphery of the affected area)

#### What has to be done:

- Enlist all houses (and persons)
- Daily visits to each house and enquire about any person developing any symptoms (like fever, cough, shortness of breath, difficulty in breathing etc.)
- In case of a person is detected to be developing symptoms of COVID-19, the same shall be brought to notice of supervisory medical officer
- Daily reporting: as per the format (Annexure V)

### III. Home Quarantine:

- Who has to be quarantined: all households and close contacts of a confirmed and suspect cases are to be home quarantined
- **Duration of home quarantine**: Those being home quarantined need to be followed up till the time test results of suspect case (whose contacts are being home quarantined and followed up) comes negative. If the test result comes positive then all such persons become 'true' contacts and have to be home quarantined for 14 days and followed up for 28 days.

#### IV. Isolation:

- Suspect cases detected on active surveillance need to be in isolated in a room in the house temporarily till the time he/she is examined by the supervisory medical officer or shifted by the designated ambulance to the designated health facility.
- Following shifting to health facility, place of temporary isolations needs to be disinfected in accordance with prescribed SOPs by 1% sodium hypochlorite

## Appendix V

S. N o.	Name	Age	Sex	Address	Date on which expose d	To be under surveill ance (till date)	Symptoma tic (Y/N). If Yes, is person isolated/re ferred	Sample taken (Y/N)	Remar ks
					<u> </u>				

## Line listing of Contact (Name of Patient): \_\_\_\_\_

(Please use separate sheet for contacts of different patients)

Sample collection proforma to be attached with the samples

#### ICMR- National Institute of Virology, Pune Specimen Referral Form for 2019 Novel Coronavirus (2019-nCoV)

INSTRUCTIONS:								
Inform the local								
<ul> <li>Seek guidance or</li> </ul>								
This form may be	e filled in an	d shared w	ith the I	DSP and a	lso ICMR-NIV ne	odal officer in	n advance.	
PERSON DETAILS								
Name of patient: .					Age:Years	SMonth	Gender: Male	Female
Address:					Date of birth	:/	/ (dd/mm	/vvvv)
City:								
State:					Email:			
EXPOSURE HISTO	RY (2 WEE	KS BEFO	RE THE	ONSET O	F SYMPTOMS	)		
Recent stay/trave	l in area (	Wuhan, Q	ר <mark>אוו: (hina):</mark>	/es N	o 🗌 If yes, s	tay/travel o	luration with da	ate
History of visit to v			et: Y				to:/	-
Close contact with					=		animal/birds Y	-
Recent travel to a		-						
Health care worke				lved in n				
Hospitalization da					Discharge da	ate:/	/	
CLINICAL SYMPTO					I.			
Date of onset of s	ymptoms:	/	/		First sympto	m:		
Symptoms	Yes No	Sympto	ms Y	es No	Symptoms	Yes No S		es No
Fever at evaluation	<u>n</u>	Cough		느님	Diarrhoea		Abdominal pair	
History of fever		Breathle			Nausea		Vomiting	
		Sore th		니니	Body-ache		Haemoptysis	느 느
Chest pain		Sputum					Nasal discharge	
Signs	Yes No	Sign		Yes No	Sign		Yes No	
Wheeze		Stridor		딤님	Lower chest	0	님님	
Nasal flaring		Crepita			Accesary mu	uscle use		
UNDERLYING MEI								
Condition	Yes No	Cond	ition	Yes No	Condition	Yes No	Condition	Yes No
Condition COPD	Yes No	<b>Cond</b> Bronch	<b>ition</b> itis		Diabetes		Hypertension	
<b>Condition</b> COPD Chronic renal dise	Yes No	<b>Cond</b> Bronch Maligna	<i>ition</i> iitis ancy				Hypertension Asthma	
Condition COPD Chronic renal dise IMMUNOCOMPR	Yes No DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD	<b>Cond</b> Bronch Maligna ONDITIO	<b>ition</b> iitis ancy <u>N</u> : YES ,		Diabetes Heart disea		Hypertension	
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION	Yes No See OMISED Co I, TREATM	<b>Cond</b> Bronch Maligna ONDITIO	<b>ition</b> iitis ancy <u>N</u> : YES ,		Diabetes Heart disea		Hypertension Asthma	
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION	Yes         No           Image: Image in the second seco	<b>Cond</b> Bronch Maligna ONDITIO	<b>ition</b> iitis ancy <u>N</u> : YES ,		Diabetes Heart disea N <u>DIAGNOSIS</u> :	ase 🗌 🗌 Other:	Hypertension Asthma	
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGM	Yes No See OMISED Co J, TREATM ate:/	<b>Cond</b> Bronch Malign ONDITIO ENT AND	<b>ition</b> iitis ancy <u>N</u> : YES ,		Diabetes Heart disea N <u>DIAGNOSIS:</u> ETIOLOGY IDE	Other:	Hypertension Asthma	
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION	Yes No	<b>Cond</b> Bronch Malign ONDITIO ENT AND	<b>ition</b> iitis ancy <u>N</u> : YES ,		Diabetes Heart disea N <u>DIAGNOSIS:</u> ETIOLOGY IDE	Other:	Hypertension Asthma COURSE: YES / NO	
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION DIFFERENTIAL DIAGA ATYPICAL PRESENTA	Yes No	<b>Cond</b> Bronch Malign ONDITIO ENT AND	ition iitis ancy <u>N</u> : YES , D INVES		Diabetes Heart disea N DIAGNOSIS: ETIOLOGY IDI UNUSUAL / L OUTCOME da	Other:	Hypertension Asthma COURSE: YES / NC	
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge	Yes Na ase OMISED CO I, TREATM ate:/ IOSIS: TION: YES/ e / Death /	<b>Cond</b> Bronch Malign: ONDITIO ENT AND ENT AND NO	ition itis ancy <u>N</u> : YES / D INVES		Diabetes Heart disea N DIAGNOSIS: ETIOLOGY IDI UNUSUAL / L OUTCOME da	Other:	Hypertension Asthma COURSE: YES / NC / O Treatment	
Condition COPD Chronic renal dise IMMUNOCOMPRI HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment	Yes No Yes No Yes No Yes No	Cond Bronch Malign: ONDITIO ENT ANE MO Treatm	ition itis ancy <u>N</u> : YES / D INVES		Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDI UNUSUAL / L OUTCOME da Treatment	Other:	Hypertension Asthma COURSE: YES / NC / O Treatment Steroids	Yes No
Condition COPD Chronic renal dise IMMUNOCOMPRI HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics	Yes         Na           ase	<ul> <li>Cond</li> <li>Bronch</li> <li>Malign</li> <li>ONDITIO</li> <li>ENT AND</li> <li>ENT AND</li> <li>NO</li> <li>Treatm</li> <li>Ventila</li> <li>CPAP</li> </ul>	ition iitis ancy <u>N</u> : YES / <b>DINVES</b> <b>DINVES</b> ent tion		Diabetes Heart disea DIAGNOSIS: ETIOLOGY ID UNUSUAL/L OUTCOME da Treatment Antivirals Bronchodil	SNTIFIED: UNEXPECTED Ate:	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other:	Yes No
Condition COPD Chronic renal dise IMMUNOCOMPRI HOSPITALIZATION HOSPITALIZATION differential Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc	Yes         Nu           ase	Cond Bronch Malign. ONDITIO ENT AND 	ition iitis ancy N: YES / D INVES ent tion ytes (%)		Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDE UNUSUAL / L OUTCOME di Treatment Antivirals Bronchodil Hb:	ASE Check Content of the second secon	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: cyte count): Neutrophils (S	Yes No
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION DIFFERENTIAL DIAGA ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%):	Yes No ase DMISED C UMISED C UTREATM ate:/	Cond Bronch Maligno ONDITIO ENT ANE  NO Treatm Ventila CPAP atocrit: Lymphoc bophil (%)	ition iitis ancy <u>N</u> : YES / <b>D INVES</b> ent tion ytes (%)	( NO     ( NO)	Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDE UNUSUAL / L OUTCOME di Treatment Antivirals Bronchodil . Hb: 	Ase Cherrich Content of the content	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Cyte count): Neutrophils (5 	Yes No
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%): Investigation detai	Yes No ase OMISED C J, TREATM ate:/ JOSIS: TION: YES/ a / Death / Yes No  Yes No  Pags: Haema yte count: 	Cond Bronch Malign ONDITIO ENT ANE  NO Treatm Ventila CPAP atocrit: Lymphoc bophil (%) K ray: Yes	ition iitis ancy N: YES / D INVES ent tion ytes (%)	V NO V NO TIGATION Ves No Ves No	Diabetes Heart disea ETIOLOGY IDF UNUSUAL / L OUTCOME da Treatment Antivirals Bronchodill Hb:	Ase Other: Other: INEXPECTED INEX	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Syte count): Neutrophils (5 	Yes No %):
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION DIFFERENTIAL DIAGA ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%):	Yes No ase OMISED C J, TREATM ate:/ JOSIS: TION: YES/ a / Death / Yes No  Yes No  Pags: Haema yte count: 	Cond Bronch Malign ONDITIO ENT ANE  NO Treatm Ventila CPAP atocrit: Lymphoc bophil (%) K ray: Yes	ition iitis ancy N: YES / D INVES ent tion ytes (%)	V NO V NO TIGATION Ves No Ves No	Diabetes Heart disea ETIOLOGY IDF UNUSUAL / L OUTCOME da Treatment Antivirals Bronchodill Hb:	Ase Other: Other: INEXPECTED INEX	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Syte count): Neutrophils (5 	Yes No %):
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%): Investigation detai	Yes No ase OMISED C J, TREATM te: OSIS: TION: YES / a / Death / Yes No  Yes No  Yes No  Se: Haema yte count: ts: Chest ) ags (If any)	Cond Bronch Malign ONDITIO ENT AND ENT AND Work Ventila CPAP atocrit: Lymphoc Cpaphil (%) K ray: Yes	ition itis ancy N: YES / D INVES ent tion ytes (%) : No		Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDD UNUSUAL / L OUTCOME da Treatment Antivirals Bronchodil . Hb: 	Ase Other: Other: INEXPECTED INEX	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Syte count): Neutrophils (5 	Yes No %):
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION DIFFERENTIAL DIAGA ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%): Investigation detai Blood culture findii	Yes         No           ase	Cond Bronch Malign ONDITIO ENT AND ENT AND Work Ventila CPAP atocrit: Lymphoc Cpaphil (%) K ray: Yes	ition itis ancy N: YES / D INVES ent tion ytes (%) : No		Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDD UNUSUAL / L OUTCOME da Treatment Antivirals Bronchodil . Hb: 	Ase Cher: Other: Other: INTIFIED: INEXPECTED Ate: Yes N Yes N Ators Cleuko WBC (leuko b): WBC (leuko c): m cher: n details:	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Syte count): Neutrophils (5 	Yes No %):
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION dt DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%): Investigation detai Blood culture findii SPECIMEN INFOR	Yes         No           ase	Cond Bronch Malign ONDITIO ENT AND ENT AND MO Treatm Ventila CPAP Treatm Ventila CPAP Atocrit: Lymphoc CPAP Atocrit: Lymphoc Rom REE	ition itis ancy N: YES / NINVES INVES ent tion ytes (%) : No FERRING	Yes No Yes No Platel Yes No Agence For	Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDD UNUSUAL / L OUTCOME de Treatment Antivirals Bronchodil . Hb: Monocytes (% et (Thrombocy s (findings): er investigation	Ase Cher: Other: Other: INTIFIED: INEXPECTED Ate: Yes N Yes N Ators Cleuko WBC (leuko b): WBC (leuko c): m cher: n details:	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Neutrophils (5 	Yes No 
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%): Investigation detai Blood culture findii SPECIMEN INFORI	Yes         No           ase	Cond Bronch Malign ONDITIO ENT AND ENT AND MO Treatm Ventila CPAP Treatm Ventila CPAP Atocrit: Lymphoc CPAP Atocrit: Lymphoc Rom REE	ition itis ancy N: YES / NINVES INVES ent tion ytes (%) : No FERRING	Yes No Yes No Platel Yes No S AGENC FOR OFFICE	Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDD UNUSUAL / L OUTCOME de Treatment Antivirals Bronchodil . Hb: Monocytes (% et (Thrombocy s (findings): er investigation	Ase Cher: Other: Other: INTIFIED: INEXPECTED Ate: Yes N Yes N Ators Cleuko WBC (leuko b): WBC (leuko c): m cher: n details:	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Neutrophils (5 	Yes No 
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%): Investigation detai Blood culture findii SPECIMEN INFORI Specimen type 1. BAL/ETA/	Yes         No           ase	Cond Bronch Malign ONDITIO ENT AND ENT AND MO Treatm Ventila CPAP Treatm Ventila CPAP Atocrit: Lymphoc CPAP Atocrit: Lymphoc Rom REE	ition itis ancy N: YES / NINVES INVES ent tion ytes (%) : No FERRING	Yes No Yes No Platel Yes No Agence For	Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDD UNUSUAL / L OUTCOME de Treatment Antivirals Bronchodil . Hb: Monocytes (% et (Thrombocy s (findings): er investigation	Ase Cher: Other: Other: INTIFIED: INEXPECTED Ate: Yes N Yes N Ators Cleuko WBC (leuko b): WBC (leuko c): m cher: n details:	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Neutrophils (5 	Yes No 
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION dt DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoc Basophils (%): Investigation detai Blood culture findin SPECIMEN INFORI Specimen type 1. BAL/ETA/ 2.TS/NPS/NS	Yes         No           ase	Cond Bronch Malign ONDITIO ENT AND ENT AND MO Treatm Ventila CPAP Treatm Ventila CPAP Atocrit: Lymphoc CPAP Atocrit: Lymphoc Rom REE	ition itis ancy N: YES / NINVES INVES ent tion ytes (%) : No FERRING	Yes No Yes No Yes No Yes No OHIGHTIGATION Yes No OHIGHTIGATION Yes No OHIGHTIGATION	Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDD UNUSUAL / L OUTCOME de Treatment Antivirals Bronchodil . Hb: Monocytes (% et (Thrombocy s (findings): er investigation	Ase Cher: Other: Other: INTIFIED: INEXPECTED Ate: Yes N Yes N Ators Cleuko WBC (leuko b): WBC (leuko c): m cher: n details:	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Neutrophils (5 	Yes No 
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoc Basophils (%): Investigation detai Blood culture findin SPECIMEN INFOR Specimen type 1. BAL/ETA/ 2.TS/NPS/NS 3. Blood in EDTA	Yes         No           ase	Cond Bronch Malign ONDITIO ENT AND ENT AND MO Treatm Ventila CPAP Treatm Ventila CPAP Atocrit: Lymphoc CPAP Atocrit: Lymphoc Rom REE	ition itis ancy N: YES / NINVES INVES ent tion ytes (%) : No FERRING	Yes No TIGATIOI Yes No Yes No Head Yes No	Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDD UNUSUAL / L OUTCOME de Treatment Antivirals Bronchodil . Hb: Monocytes (% et (Thrombocy s (findings): er investigation	Ase Cher: Other: Other: INTIFIED: INEXPECTED Ate: Yes N Yes N Ators Cleuko WBC (leuko b): WBC (leuko c): m cher: n details:	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Neutrophils (5 	Yes No 
Condition COPD Chronic renal dise IMMUNOCOMPRI HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%): Investigation detai Blood culture findii SPECIMEN INFORI Specimen type 1. BAL/ETA/ 2.TS/NPS/NS 3. Blood in EDTA 4. Acute sera	Yes         No           ase	Cond Bronch Malign ONDITIO ENT AND ENT AND MO Treatm Ventila CPAP Treatm Ventila CPAP Atocrit: Lymphoc CPAP Atocrit: Lymphoc Rom REE	ition itis ancy N: YES / NINVES INVES ent tion ytes (%) : No FERRING	Yes No TIGATIOI Yes No Yes No Head Yes No	Diabetes Heart disea DIAGNOSIS: ETIOLOGY IDD UNUSUAL / L OUTCOME de Treatment Antivirals Bronchodil . Hb: Monocytes (% et (Thrombocy s (findings): er investigation	Ase Cher: Other: Other: INTIFIED: INEXPECTED Ate: Yes N Yes N Ators Cleuko WBC (leuko b): WBC (leuko c): m cher: n details:	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Neutrophils (5 	Yes No 
Condition COPD Chronic renal dise IMMUNOCOMPR HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findii Differential Leukoc Basophils (%): Investigation detai Blood culture findii SPECIMEN INFOR Specimen type 1. BAL/ETA/ 2.TS/NPS/NS 3. Blood in EDTA 4. Acute sera 5 Convalescent	Yes No ase I, TREATM ISED C I, TREATM ISE: IDON: YES / Death /_ Yes No IIION: YES / Yes No IIION: YES / Yes No IIION: YES / YE	Cond Bronch Malign: ONDITIO ENT ANE  NO Treatm Ventila CPAP atocrit: Lymphoc hophil (%) K ray: Yes  ROM REF on date	ition iitis ancy N: YES / O INVES ent tion wytes (%) :	Yes No TIGATIOI Yes No Yes No Platel Yes Office Use ICMR- NIV	Diabetes Heart disea DIAGNOSIS: ETIOLOGY ID UNUSUAL / L OUTCOME da Treatment Antivirals Bronchodil . Hb:	Ase Other: Other: INTIFIED: INEXPECTED Aters Other: Yes N Aters Other: WBC (leukoris): MBC (leukoris): Tes: Tes: Tes: Other: Tes: Other: Other: Other: NEXPECTED Tes: Other	Hypertension Asthma COURSE: YES / NC / o Treatment Steroids Other: Other: Neutrophils (5 	Yes         No

PLEASE REFER THE CASE DEFINITION CHECKLIST ON PAGE 2. FOR SPECIMEN COLLECTION GUIDELINES, VISIT **WWW.niv.co.in** For any sharing of information or for any query, contact Dr. Yogesh Gurav Scientist E (020-26006290/26006390). Page 1 of 2

#### ICMR- National Institute of Virology, Pune Specimen Referral Form for 2019 Novel Coronavirus (2019-nCoV)

Name of the patient:	Age:yearsmonths
----------------------	-----------------

Note: Please ensure that the case definition should be strictly followed. Please encircle the correct response (Yes/No)

#### CASE DEFINITION

#### 1. Severe Acute Respiratory Illness (SARI), with history of fever YES / NO • YES / NO cough YES / NO requiring admission to hospital WITH no other etiology explains the clinical presentation YES / NO (clinicians should also be alert to the possibility of atypical presentations in patients who are immunocompromised); AND any of the following A history of travel to Wuhan, Hubei Province China in the 14 days prior to symptom onset. YES / NO • the disease occurs in a health care worker who has been working in an environment where patients with severe acute respiratory infections are being cared for, without regard to YES / NO place of residence or history of travel the person develops an unusual or unexpected clinical course, especially sudden deterioration despite appropriate treatment, without regard to place of residence or history of travel, even if another etiology has been identified that fully explains the clinical presentation. YES /NO 2. Individuals with acute respiratory illness of any degree of severity who, within 14 days before onset of illness, had any of the following exposures: close physical contact with a confirmed case of nCoV infection, while that patient was symptomatic; YES / NO • a healthcare facility in a country where hospital associated nCoV infections have been reported; YES / NO direct contact with animals (if animal source is identified) in countries where the nCoV is known to be circulating in animal populations or where human infections have occurred as a result of presumed zoonotic transmission\*. YES / NO \* To be added once/if animal source is identified as a source of infection EMAIL ID OF THE HEALTH AUTHORITY (FOR SENDING THE REPORT): ..... Name of Doctor: ..... Hospital Name/address: .....

Phone/mobile number: ..... Signature and date: .....

## Appendix-VII

Sector	Name of the	Purpose for	Vehicle	Driver	Contact
	Sector	Vehicle	Regn.	name	Number
		Deployed	number		
A		House to house surveillance			
		Supervisory Staff			
В		House to house surveillance			
		Supervisory Staff			
C		House to house surveillance			
		Supervisory Staff			

# Transportation arrangement for containment Operation

## Appendix-VIII

Identified Sectors for Public Education Outreach and rostering of identified communication staff

Sector	Name	of	Name of	Contact	Name of	Contact
	Municipal v	ward/	Municipal/	Number	Supervisory	Number
	village		Panchayat		BEE	
			staff			

Appendix-IX

Cluster Containment						
Format for daily report of COVID-19 virus disease						
		Date :				
State:	District:	Block :	Epicentre:			
Total No. of Village in the block:	Fotal No. of Village in the block:     No. of affected Municipalty /village:					

A) A 1 Population Based Information	No. of villages/municipality/localities	Population Surveyed(Daily)	Population surveyed (Cumulative)
0-3 Km Population from Epicenter	10. or vinages/municipanty/locanties		
A-2 Morbidity data			
		Daily	Cumulative
Persons with fever / symptoms consistent (only			
new Cases) with COVID-19 virus disease	0-3 Km from Epicenter		
	_		
B) Hospital based Information: Name of Hospita	al	••••••	
In patient		Daily	Cumulative
Suspect COVID-19 viral disease cases			
Laboratory Confirmed case of COVID-19 virus dis	ease		
No of deaths (suspected or confirmed)			
D) Contact Tracing			

Number of contacts under surveillance

E) Laboratory Testing	Number of Samples taken		Number of Samples found Positive	
	Daily	Cumulative	Daily	Cumulative

F) Public Education outreach	No of houses in 0-3 km	No. of houses Visited	Percentage
Villages covered by Public Education Outreach			

G) Monitoring Health Staff						
Health personnel deployed in field including medical officers, Health supervisors/health workers etc.		Health personnel deployed in field complaining of Fever/ symptoms consistent with COVID-19 virus disease				
Hospital staff including Medical Officers, Nurses, Attendants etc.		Hospital staff complaining of Fever/ symptoms consistent with COVID-19 virus disease				

#### H) Stock Position

Item	Previous days stock at District HQ	Consumed for the day	Stock at hand( s)	Stock to be requisitioned if any
PPE				
N-95 Masks				
Triple layer surgical				
mask				

Note: Daily report to be faxed by 11.00 a.m.

•

.

Director NCDC (Fax No: 011-23922677; 011-23921401)

Director EMR (Fax No: 011- 23061457)

Signature DSO

(Name & Desg. Of the reporting officer) Phone No. of DSO